VasoMedical–BIOX to Exhibit Proprietary Products at CMEF in Chongqing, China
WESTBURY, N.Y. – October 15, 2014 - VasoMedical, Inc.(“VasoMedical”) (“the Company”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices, including EECP® Therapy systems, the gold standard of External CounterPulsation therapy, and MobiCareTM, the latest in wireless patient monitoring technology, announced today that its wholly owned subsidiary BIOX Instruments Co. Ltd., will exhibit at the 72nd Chinese International Medical Equipment Fair (CMEF) October 23 – 26, 2014 in Chongqing, China.
As one of the leading medical device shows in the Asia-Pacific market, the autumn CMEF is expected to draw 60,000 visitors from over 100 countries to Chongqing, a major city in Southwest China. VasoMedical-BIOX' exhibition will be located in booth #HN6-B01 at the Chongqing International Expo Center.
The Company will showcase its BIOXTM series ambulatory monitoring products and the MobiCareTM wireless patient monitoring system, a multi-parameter patient monitor that wirelessly transmits the patient's vital signs, including ECG, respiration, SpO2, temperature and NIBP, to a bedside receiver or tablet display, from which the information can be further relayed for remote viewing and analysis.
“With an already established reputation in China for high quality medical devices, we are looking to expand our presence in the growing Chinese market. Encouraged by the enthusiastic reception to MobiCareTM patient monitors, which were introduced in China earlier this year, the Company is poised to join in the growing global telemedicine market,” stated Qiuming Shen, President of BIOX.
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through four wholly owned subsidiaries: VasoMedical Solutions, Inc., VasoMedical Global Corp., Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, and VasoHealthcare IT Corp. VasoMedical Solutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments; and VasoHealthcare IT is a national value added reseller of GE Healthcare IT's Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support.. Additional information is available on the Company's website at www.vasomedical.com
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreements; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Michael J. Beecher/Amanda Jiang